Kidney Transplant Immunosuppression
Conditions
Keywords
Kidney Transplantation, Immunosuppression, Immune monitoring
Brief summary
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
Detailed description
Background: The management of renal transplant recipients is challenging in keeping a delicate balance of immunosuppression to avoid either infection (overimmunosuppression), or rejection (under-immunosuppression). Conventional clinical parameters are not adequate enough. ImmuKnow (Cylex Inc, Columbia, MD) is an FDA-cleared assay for the detection of cell mediated immune response in populations undergoing immunosuppressive therapy for organ transplant. There have been limited retrospective studies discussing the effectiveness of the ImmuKnow assay. There is no prospective head-to-head trial showing the benefits of periodic ImmuKnow testing. Objective: To demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in de novo renal transplant recipients Patients and Methods: A prospective, randomized, pilot, controlled 12-month study to compare the outcomes of 2 cohorts of de novo renal transplant patients will be conducted. The outcomes that will be investigated include a combined infection rate (primary end-point), separate infection rates and episodes, acute rejection rate and episodes, quality of life, graft and patient survivals (all secondary end-points). Biopsy of the transplanted kidney is used to confirm rejection whenever possible. Among the study cohort, the patients' immunosuppressants will be adjusted according to the results of a serial ImmuKnow assay besides using conventional clinical parameters; whereas among the control cohort the patients' immunosuppressants will be adjusted according to conventional clinical parameters. Expected Results: At the end of this study we will be able to learn whether the study cohort patients have less infection, less acute rejection, better allograft function, better quality of life, and better graft or patient survivals.
Interventions
DRUGadjustment of immunosuppressant dosages
adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
DRUGadjustment of the dosages of immunosuppressants
adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
Sponsors
CAMC Health System
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. De novo kidney transplant patients who are eligible for kidney transplant according to UNOS criteria and agree to participate in the study. 2. Patients of both sex aged between 18 to 80 years.
Exclusion criteria
* Any patient with a known immunocompromised disease (e.g. patients with AIDS) or leukocytosis(\>15,000u/L)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the combo-infection rates of the 2 cohorts of renal transplant recipients within the 12-month period after a de novo kidney transplantation | 12 months | The combo-infection is defined as: If a patient either has new onset culture/or serology/or PCR positive bacterial or viral infections; or moderate neutropenia (absolute netrophile count \< 1000/microL) or need GCS-F injection or has fever \>38.5 % for longer than 24 hrs then he/she is called to have combo- infection. Percentage of such patients will be compared in Immuknow vs. control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event numbers of infection | 12 months | 1.1 Event numbers of new onset infections;1.2 Episodes of patients with moderate neutropenia (\< 1000/microL), 1.3 Episodes of patients needing GCS-F; 1.4. Episodes of fever \>38.5 % \>= 24 hrs. |
| Percentage of Infection | 12 months | 2.1 percentages of patients with new onset infections; 2.2 percentages of patients with moderate neutropenia, 2.3 percentages of patients needing GCS-F injection; 2.4 percentages of fever \>38.5 \>= 24 hrs. |
| Acute rejection | 12 months | 3.1 Episodes of acute rejection; 3.2 Percentages of Acute Rejection. |
| Life Quality | 12 months | 4.SF-8 QOL index |
| Allograft function | 12 months | 5.1 serum creatinine levels 5.2 estimated GFR |
| Graft Survival | 12 months | 6\. Graft survival |
| Patient Survival | 12 months | 7\. Patient survival |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORS Jeff Chueh, MD PhD
CAMC Health System, Charleston, WV
STUDY_DIRECTORBashir Sankari, MD
CAMC Health System, Charleston, Wv
Outcome results
None listed